InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (11 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
11
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the detailed record of transactions filed by Friedl-Naderer Johanna, Directeur Commercial. Insider active across 2 companies, notably Dyne Therapeutics, Inc.. Aggregated, 16 reports have been published. Breakdown: 0 buy · 11 sells. Total volume traded: €80k. History available since 2 March 2022. The latest transaction was disclosed on 4 September 2026 (Cession). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Friedl-Naderer Johanna
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations16 total
900 shares@ US$24.35Common StockSEC:0001915598-26-000005:0
185 shares@ US$18.88Common StockSEC:0001915598-26-000005:1
226 shares@ US$26.280.0001% mcap19.3% of flowCommon StockSEC:0001915598-26-000004:0
145 sharesCommon StockSEC:0001915598-26-000002:0
228 shares@ US$18.360.0001% mcap50.0% of flowCommon StockSEC:0001193125-26-223984:0
148 shares@ US$14.908.8% of flowCommon StockSEC:0001193125-26-096523:0
60,000 shares0Common StockSEC:0001193125-26-055063:0
144 shares@ US$20.7213.1% of flowCommon StockSEC:0001193125-25-309636:0
894 shares@ US$13.2759.7% of flowCommon StockSEC:0000950170-25-113545:0
146 shares@ US$13.3524.8% of flowCommon StockSEC:0000950170-25-083033:0
143 shares@ US$12.1218.2% of flowCommon StockSEC:0000950170-25-038750:0
37,800 shares0Common StockSEC:0000950170-24-134078:0
58,400 shares0Common StockSEC:0000950170-24-103033:0
1,482 shares@ US$22.82100.0% of flowCommon StockSEC:0001209191-23-016629:0
60,000 shares0Common StockSEC:0001209191-23-012991:0
90,000 shares0Common StockSEC:0001209191-22-016929:0
16 of 16 declarations
About Friedl-Naderer Johanna
Friedl-Naderer Johanna is Director Commercial and has disclosed 13 transactions in total. In the recent filings available, these relate to sales between 2022-03-08 and 2026-06-17, for total sales of EUR 53407, with transactions reported in Vir Biotechnology, Inc. and Dyne Therapeutics, Inc.
